Top Factor Driving Giant-Cell Arteritis Market Growth in 2025: Embracing Personalized Medicine A Shift Towards Tailored Healthcare Solutions

How Are the key drivers contributing to the expansion of the giant-cell arteritis market?
The growing focus on personalized medicine is predicted to boost the growth of the giant-cell arteritis (GCA) market. Personalized medicine tailors treatments to an individual's genetics, lifestyle, and environment. Advances in genomics, biotechnology, and data analytics have enabled the development of more targeted therapies that enhance treatment effectiveness and minimize side effects. In the case of GCA, personalized medicine allows for tailored treatments based on genetic factors and immune responses. For example, in February 2024, the Personalized Medicine Coalition (PMC) reported that personalized medicines made up over one-third of new FDA drug approvals in 2023, including treatments for rare diseases and cancers. This emphasis on personalized medicine is driving the growth of the GCA market.

Get Your Giant-Cell Arteritis Market Report Here:
https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

What growth opportunities are expected to drive the giant-cell arteritis market's CAGR through 2034?
The giant-cell arteritis market has experienced moderate growth. It is expected to increase from $1.07 billion in 2024 to $1.12 billion in 2025, at a CAGR of 5.3%. This growth is driven by epidemiological studies, genetic insights, the rising adoption of biologics, improved diagnostic techniques, and the development of targeted therapies and biologics.

The giant-cell arteritis market is expected to grow to $1.36 billion by 2029, at a CAGR of 5.0%. Growth is driven by higher diagnosis rates, aging populations, rising healthcare expenditure, and patient advocacy. Key trends include biomarker identification, molecular-targeted therapies, advanced imaging techniques, drug delivery innovations, and AI for predictive analytics.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

What are the emerging trends shaping the future of the giant-cell arteritis market?
Companies in the giant-cell arteritis market are expanding treatment options with biosimilars to address unmet medical needs. A biosimilar is a biologic drug closely resembling an existing approved product. For example, in April 2024, Fresenius SE & Co. KGaA, a German healthcare company, launched Tocilizumab-aazg in the US, a biosimilar approved for treating chronic autoimmune conditions like rheumatoid arthritis and giant cell arteritis, following successful clinical trials.

Which growth-oriented segments of the giant-cell arteritis market are leading the industry's development?
The giant-cell arteritis market covered in this report is segmented -

1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin
2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action
3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:
1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy
2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy
3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids
4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17162

Which region dominates the giant-cell arteritis market?
North America was the largest region in the giant-cell arteritis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What companies are at the forefront of innovation in the giant-cell arteritis market?
Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=17162&type=smp

What Is Covered In The Giant-Cell Arteritis Global Market Report?

•Market Size Forecast: Examine the giant-cell arteritis market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the giant-cell arteritis market for a structured understanding.
•Key Players Overview: Analyze major players in the giant-cell arteritis market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the giant-cell arteritis market.
•Segment Contributions: Evaluate how different segments drive overall growth in the giant-cell arteritis market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the giant-cell arteritis market.
•Industry Challenges: Identify potential risks and obstacles affecting the giant-cell arteritis market.
•Competitive Landscape: Review strategic developments in the giant-cell arteritis market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.